Capecitabine With Mitomycin Reduces Acute Hematologic Toxicity and Treatment Delays in Patients Undergoing Definitive Chemoradiation Using Intensity Modulated Radiation Therapy for Anal Cancer.

摘要: Purpose To assess the impact on acute toxicity of replacing 5-fluorouracil (5-FU) with capecitabine in definitive chemoradiation for patients anal squamous cell carcinoma (ASCC). Methods and Materials We retrospectively reviewed records 107 consecutive nonmetastatic ASCC treated from January 2009 to May 2014. In 2011, based noninferiority versus 5-FU, our institutional practice shifted use instead 5-FU ASCC. Of patients, 63 were infusional (1000 mg/m 2 /day 4 days) mitomycin C (MMC) (10 mg/m ) during weeks 1 5, 44 (825 mg/m twice daily) Monday through Friday throughout radiation therapy (RT) MMC 5. The incidence grade 3 4 was compared between groups. Results median age at diagnosis 59 years, 78 (73%) female. patient characteristics similar treatment All both groups intensity modulated RT (median dose, 56 Gy). group, 52% experienced neutropenia 20% group ( P =.001). Treatment breaks resulting toxicity, primarily related 3+ hematologic necessary 42% 16% those =.006). Conclusions Pelvic plus well tolerated appeared have less 3+ acute hematologic fewer interruptions than a population undergoing 5-FU.